Therapeutic apheresis for cancer related hemolytic uremic syndrome

Therapeutic Apheresis

Volumn 4, Issue 3, 2000, Pages 201-206

  Kaplan, Andre A ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cancer; Hemolytic uremic syndrome; Immunoadsorption; Plasmapheresis; Therapeutic plasma exchange; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ESTRAMUSTINE; FLUOROURACIL; FRESH FROZEN PLASMA; GEMCITABINE; MITOMYCIN C; SEMUSTINE; TACROLIMUS;

APHERESIS; BONE MARROW TRANSPLANTATION; CONFERENCE PAPER; DISSEMINATED CANCER; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOADSORPTION; KIDNEY FAILURE; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTINEOPLASTIC AGENTS; BLOOD COMPONENT REMOVAL; BONE MARROW TRANSPLANTATION; DISEASE PROGRESSION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSORBENT TECHNIQUES; NEOPLASMS; PLASMA EXCHANGE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0033948439     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2000.00193.x     Document Type: Conference Paper

References (37)

1. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler W, Solenthaler M, Lammle B. Von Willebrand factor - cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Eng J Med 1998;339:1578-84.
2. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7.
3. Boyce TG, Serdlow DL, Griffin PM. Escherichia coli 0157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995;333: 364-8.
4. Koster F, Levin J, Walker L, Tung K, Gilman R, Rahaman M, Majid A, Islam S, Williams R. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med. 1978;298:927-33.
5. Gordon LI, Kwaan HC. Cancer and drug associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:140-7.
6. Charba D, Moake JL, Harris MA. Abnormalities of von Willebrand multimers in drug-associated thrombotic microangiopathies. Am J Hematol 1993;42:268-77.
7. Canpolat C, Pearson P, Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer 1994;74:3059-62.
8. Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JPS, Rudnick MR, Elfenbein IB, Narins RG. Thrombotic angiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1994;101:41-4.
9. Hanna W, Crauss S, Regestor R, Murphey W. Renal disease after mitomycin C therapy. Cancer 1981;48:2583-8.
10. Atkinson K, Biggs JC, Hayes J, Ralston M, Dodds AJ, Concannon J, Naidoo D. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: Three distinct syndromes. Br J Haematol 1983;54: 59-67.
11. Ucar A, Fernandez HF, Byrnes JJ, Lian EC, Haarington WJ. Thrombotic Microangiopathy and Retroviral Infections: A 13-year experience. Am J Hematol 1994;45:304-9.
12. Mokrzycki MH, Rickles FR, Kaplan AA, Kohn OF. Thrombotic thrombocytopenic purpura in pregnancy: Successful treatment with plasma exchange. Case report and review of the literature. Blood Purif 1995;13:271-82.
13. Ezra Y, Rose M, Eldor A. Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: A clinical study of 16 pregnancies. Am J Hematol 1996;51:1-6.
14. Brain M, Dacie J, Hourhaine DB. Microangiopathic hemolytic anemia: The possible role of vascular lesions in pathogenesis. Br J Haematol 1962;18:183-93.
15. Lohrmann HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma: Report of eight cases. Ann Intern Med 1973;79:368-75.
16. Murgo A. Thrombotic microantiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987;24:161-77.
17. Moake JL, Byrnes JJ. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematology/Oncology Clinics of North America 1996;10:485-97.
18. Grace AA, Barradas MA, Mikhailidis DP, Jeremy JY, Moorhead JF, Sweny P, Dandona P. Cyclosporin A enhances platelet aggregation. Kidney Int 1987;32:889.
19. Brown Z, Neild GH. Cyclosporin inhibits prostacyclin production by cultured human endothelial cells. Trans Proc 1987; 19:1178.
20. Licciardello JTW, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985;42:296-300.
21. Charba D, Moake JL, Harris MA. Abnormalities of von Willebrand multimers in drug-associated thrombotic microangiopathies. Am J Hematol 1993;42:268.
22. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986;58:1428-36.
23. Samtleben W, Schmidt B, Gurland HJ. Ex vivo and in vivo protein A perfusion: Background, basic investigations and first clinical experience. Blood Purif 1987;5:179-92.
24. Snyder HW Jr, Balint JP, Jones FR. Modultation of immunity in patients with autoimmune disease and cancer treated by extracorporeal immunoadsorption with Prosorba columns. Sem Hematol 1989;26:31-41.
25. Gjorstrup P, Watt RM. Therapeutic protein A immunoadsorption. A review. Transfusion Sci 1990;11:281-302.
26. Korec S, Schein PS, Smith FP, Neefe JR, Woolley PV, Goldberg RM, Phillips TM. Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion. J Clin Oncol 1986; 4:210-5.
27. Watson PR, Guthrie TH, Caruana RJ. Cisplatin-associated hemolytic uremic syndrome: Successful treatment with a staphylococcal protein A column. Cancer 1989;64: 1400-3.
28. Snyder HW Jr, Mittelman A, Oral A, Messerschmidt GL, Henry DH, Koree S, Bertram JH, Guthrie TH Jr, Ciavarella D, Wuest D, Perkins W, Balint JP, Cochran A, Peugot RL, Jones P. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 1993;71:1882-92.
29. D'Souza RJ, Kwan JT, Hendry BM, Fallon M, Cunningham D. Successful outcome of treating hemolytic uremic syndrome associated with cancer chemotherapy with immunoadsorption. Clin Nephrol 1997;47:58-9.
30. Palmisano J, Agraharkar M, Kaplan AA. Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange. Am J Kidney Dis 1998;32: 314-7.
31. Verburgh CA, Vermeij CG, Zijlmans JM, van Veen S, van Es LA. Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature. Nephrol Dial Transpl 1996;11:1332-7.
32. Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS. Bone marrow transplant-associated thrombotic microangiopathy: A case series. Bone Marrow Transpl 1995;15:247-53.
33. Sarode R, McFarland JG, Flomenberg N, Gasper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, Cumitta B, Lawton C, Garbright F, Gottschall J. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transpl 1995;16:271-5.
34. Chown SR, Goulden N, Cornish JM, Oakhill A, Pamphilon D, Potter MN. The role of plasma exchange for TTP/HUS post-bone marrow transplant. (correspondence). Bone Marrow Transpl 1996;17:898-9.
35. Milone J, Napal J, Bordone J, Etchegoyen O, Morales V. Complete response in severe thrombotic microangiopathy post bone marrow transplantation after multiple plasmpapheresis. Bone Marrow Transpl 1998;22:1019-21.
36. Beuno D Jr, Reardon J, Sevigny J, Kaplan AA. Extracorporeal treatment of microangiopathic thrombopathy. Annual meeting of the American Society of Nephrology, Philadelphia, PA, US.A., Oct, 1998. (abs) J Am Soc Nephrol 1998;9: 127A.
37. Zeigler ZR, Shadduck RK, Nath R, Andrews DF III. Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant-associated thrombotic microangiopathy. Bone Marrow Transpl 1996;17:81-6.